Cipla says top 50 drugs in development could bring in $30B

Indian drugmaker Cipla said it currently has 200 drugs in development and that the top 50 of those drugs have the potential to earn the company more than $30 billion. The Mumbai-based company also said it plans to expand its North American market share to 25% by 2020 and plans to devote more resources to R&D for that specific market. It also plans to seek more generics approvals there, according to a report in the Business Standard. More from FiercePharmaAsia

Read more on